- Kiplinger•23 hours ago
Forget politics. Instead, look for reasonably priced companies with competitive advantages.
- Investor's Business Daily•2 days ago
Sanofi is mulling a bid for Actelion, which has an offer from Johnson & Johnson on the table.
- Reuters•2 days ago
Novartis AG said its cancer drug, Zykadia, was twice as effective as chemotherapy in slowing the progression of a rare form of lung cancer in a late-stage study. Patients with anaplastic lymphoma kinase-positive (ALK+)advanced non-small cell lung cancer treated with Zykadia had a median progression-free survival of 16.6 months, compared to 8.1 months for those on chemotherapy. Novartis' drug also has conditional approval as a second-line treatment in Europe.
NVS : Summary for Novartis AG Common Stock - Yahoo Finance
Novartis AG (NVS)
NYSE - NYSE Real Time Price. Currency in USD
Add to watchlist
|Bid||67.08 x 500|
|Ask||67.09 x 200|
|Day's Range||66.93 - 67.22|
|52 Week Range||66.93 - 88.49|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||23.65|
|Dividend & Yield||2.72 (3.94%)|
|1y Target Est||N/A|